Peru Administrative Penalties: The Nine-Tier Ladder, UIT Fines and Defense Priorities

Regulatory information verified as of October 29, 2026

1. Key takeaways

Peru’s administrative penalties for pharmaceutical establishments and registration holders form a nine-tier ascending ladder running from light to severe: warning to the owner, legal representative or technical director (Director Técnico); suspension of the technical director; fines; cancellation of good practices certificates; suspension or cancellation of sanitary registration; suspension of manufacturing or sales; temporary closure of part or all facilities; permanent closure; and confiscation of products, devices and materials. Fines are expressed in the tax unit (Unidad Impositiva Tributaria, UIT): for 2026 the UIT is S/ 5,500 (D.S. N° 301-2025-EF, published on 2025-12-17, effective from 2026-01-01; the 2025 value was S/ 5,350). Secondary sources mention that device-related violations may reach 10 UIT; we mark that item as a practical estimate pending first-hand verification, with no definitive provision sighted. Regulatory information verified as of October 29, 2026.

2. Legal basis

3. Expert insights

Insight 1 | The ladder ascends by correctability, not by amount

The design logic of the ladder is: first give the entity a chance to correct (warnings, suspension of the technical director), then move to qualification-level measures (cancellation of good practices certificates, suspension or cancellation of sanitary registration), and only then touch operating capacity (closure of facilities, permanent closure) and physical assets (confiscation). The first two tiers are therefore a remediation window, not a terminal sanction — in the cases we have handled, what decided the outcome was usually whether a credible root-cause analysis and corrective plan were submitted in the week after the warning was issued, not which tier the case sat on.

Insight 2 | UIT-based pricing makes fine amounts float by year; budget on the current-year value

Because fines are expressed in UIT rather than a fixed sol amount, the same violation produces different actual amounts in adjacent years. The 2026 UIT is S/ 5,500, up from S/ 5,350 in 2025. As a demonstrative calculation using the 10 UIT cap mentioned in secondary sources, the corresponding amount would be approximately S/ 55,000; that cap has not been verified first-hand, and the UIT ranges assigned to specific violations have not been traced to any provision. GRZAN therefore does not write this cap into plans as a firm penalty expectation, using it only as an upper-bound reference for risk exposure.

Insight 3 | The most expensive sanction is not the fine but the supply interruption from suspension plus cancellation

The measures that hit cash flow and market share hardest are suspension of manufacturing or sales, suspension or cancellation of sanitary registration, and closure of facilities. Mechanically, these freeze both the operating activity of the certified entity and the lawful market status of the product: even after restoration, hospital tender eligibility, distributor trust and stock shelf life may already have passed their windows. We therefore prioritize defense resources on preventing escalation toward these tiers, rather than negotiating only over the fine amount.

4. Practical recommendations

1. After receiving a sanction notice, first confirm the remedy path within the statutory deadline: under the consolidated procedures text (TUPA), a reconsideración motion is filed within 15 working days, followed if necessary by an apelación; the applicable deadlines are governed by the official text in force.
2. Build a 24-hour response package: statement of facts, timeline, list of affected batches, and the quarantine and corrective actions already taken.
3. Take corrective measures to the system level: records management, allocation of responsibilities, training and verification, avoiding individual negligence as the sole root cause.
4. Recalculate financial risk exposure on the current-year UIT: for 2026 use S/ 5,500, retaining the prior-year figure of S/ 5,350 for cross-year comparisons.
5. Anticipate supply-chain impact: the moment suspension of sales or cancellation of sanitary registration is implicated, activate the substitute-entity and stock reallocation plans.
6. After remediation, request a review and retain the written closure certificate as a compliance record for subsequent inspections.

5. Verification checklist

□ The current penalty tier has been identified, and the risk of escalation toward suspension of sales or cancellation of sanitary registration has been assessed (regulatory information verified as of October 29, 2026).

□ The remedy deadline has been checked: under the practical estimate, the reconsideración decision is made within 15 working days, subject to the official text published by DIGEMID.

□ Fine amounts have been recalculated at the 2026 UIT of S/ 5,500 (D.S. N° 301-2025-EF, published 2025-12-17, effective 2026-01-01).

□ The 10 UIT cap has been marked as sourced from secondary references, a practical estimate pending first-hand verification, and has not been written into firm conclusions.

□ Where article numbers of the measures described have not been verified, the documents state that specific article numbers are pending verification and the official publication prevails.

□ The corrective plan covers the system level, including responsibilities, records, training and effectiveness verification.

□ The supply-chain continuity plan has been activated, including substitute certified entities and paths for stock disposition.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration and post-market compliance support in Peru for manufacturers, importers and authorized representatives. For assistance, contact info@grzanglobal.com.